Close Menu

NEW YORK (GenomeWeb) – Fluidigm reported after the close of the market on Thursday that its first quarter revenues grew 19 percent year over year on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.

For the three months ended March 31, 2019, Fluidigm tallied $30.1 million in revenues, up from $25.3 million a year ago and besting analysts' consensus estimate of $29.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.